bone sarcoma (Cancer)
Information
- Disease name
- bone sarcoma
- Disease ID
- DOID:0080639
- Description
- "A bone cancer that has_material_basis_in abnormally proliferating cells derives from embryonic mesoderm." [url:https\://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805807]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| TP53 | 17 | 7,668,421 | 7,687,490 | 16 |
| RB1 | 13 | 48,303,751 | 48,481,890 | 6 |
| CREBBP | 16 | 3,725,054 | 3,880,713 | 4 |
| CDKN2A | 9 | 21,968,056 | 21,974,866 | 4 |
| CDKN2B-AS1 | 9 | 21,994,778 | 22,039,498 | 4 |
| DPPA3P6 | 16 | 3,840,528 | 3,841,010 | 2 |
| ITSN2 | 2 | 24,202,864 | 24,360,536 | 2 |
| TSPAN31 | 12 | 57,745,039 | 57,750,219 | 2 |
| OMG | 17 | 31,294,647 | 31,297,239 | 2 |
| EVI2B | 17 | 31,303,770 | 31,314,054 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03462316 | Active, not recruiting | Phase 1 | NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma | May 21, 2018 | May 15, 2024 |
| NCT01803152 | Active, not recruiting | Phase 1 | Dendritic Cell Vaccine for Children and Adults With Sarcoma | January 6, 2014 | July 23, 2024 |
| NCT00592293 | Active, not recruiting | N/A | Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas | October 2006 | September 2026 |
| NCT03449108 | Active, not recruiting | Phase 2 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | April 27, 2018 | June 30, 2025 |
| NCT02301039 | Completed | Phase 2 | SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | March 2015 | July 1, 2020 |
| NCT02520128 | Completed | N/A | A Study of IMRT in Primary Bone and Soft Tissue Sarcoma | March 2016 | June 30, 2020 |
| NCT01588522 | Completed | Phase 1 | Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease | July 2012 | March 2017 |
| NCT01336803 | Completed | Phase 2 | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI | August 2011 | October 2023 |
| NCT02384473 | Completed | Early Phase 1 | Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma | December 24, 2014 | January 19, 2024 |
| NCT04963517 | Completed | Phase 2/Phase 3 | Exercise Intervention for Bone Tumor Patients | August 7, 2021 | May 1, 2022 |
| NCT00525057 | Completed | N/A | Dalteparin in Preventing DVT in Participants With Cancer | July 7, 2006 | June 19, 2020 |
| NCT06202599 | Completed | Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance | November 25, 2021 | November 15, 2023 | |
| NCT03244020 | Enrolling by invitation | Phase 4 | LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology | February 16, 2018 | July 1, 2028 |
| NCT05515068 | Not yet recruiting | Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas | September 2022 | March 2032 | |
| NCT06409013 | Recruiting | Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma | March 14, 2024 | March 30, 2027 | |
| NCT02811523 | Recruiting | Phase 1 | In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma | February 2016 | February 2025 |
| NCT03277924 | Recruiting | Phase 1/Phase 2 | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas | May 31, 2017 | June 30, 2025 |
| NCT03442465 | Recruiting | Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas | February 14, 2018 | February 14, 2025 | |
| NCT04055220 | Recruiting | N/A | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | March 3, 2020 | October 1, 2026 |
| NCT04181970 | Recruiting | Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK | June 30, 2019 | September 30, 2025 | |
| NCT04616248 | Recruiting | Phase 1 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | January 9, 2023 | January 9, 2026 |
| NCT04634227 | Recruiting | Early Phase 1 | Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) | November 24, 2020 | August 31, 2024 |
| NCT04698785 | Recruiting | Phase 2 | Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients | July 21, 2021 | July 21, 2026 |
| NCT05033288 | Recruiting | Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone | January 20, 2022 | August 30, 2028 | |
| NCT05051059 | Recruiting | N/A | Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients | October 1, 2021 | April 2024 |
| NCT05621668 | Recruiting | Phase 1 | A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma | September 8, 2023 | September 30, 2025 |
| NCT05746429 | Recruiting | N/A | Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Bone Sarcoma | April 6, 2023 | October 2025 |
| NCT06129903 | Recruiting | N/A | Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma | November 7, 2023 | November 7, 2026 |
| NCT03468075 | Terminated | Phase 2 | Gemcitabine Plus Ascorbate for Sarcoma in Adults | July 11, 2018 | October 19, 2020 |
| NCT02982486 | Unknown status | Phase 2 | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | December 2017 | December 2020 |
| NCT04906876 | Withdrawn | Phase 2 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | September 2021 | July 2025 |
| NCT05116800 | Withdrawn | Phase 2 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | March 1, 2022 | August 2030 |
| NCT04877587 | Withdrawn | Early Phase 1 | Gemcitabine With Ascorbate Including Adolescents | January 2023 | May 31, 2025 |
- Disase is a (Disease Ontology)
- DOID:184